Applied NeuroSolutions Press Releases APPLIED NEUROSOLUTIONS ANNOUNCES 2005 RESULTS - Company Provides Corporate Update - March 23, 2006 Applied NeuroSolutions’ Founding Scientist Quoted In Investor’s Business Daily (IBD) - January 09, 2006 Increase in Specific, Abnormal Brain Protein May Predict Onset of Alzheimer’s Disease, Study Shows - January 04, 2006 Applied NeuroSolutions Renews Agreement with Peter Davies, Ph.D. - December 12, 2005 Applied NeuroSolutions Retains Financial Dynamics as its Financial Communications and Investor Relations Agency - December 06, 2005 Applied NeuroSolutions Appoints Inamed Executive Robert S. Vaters to its Board of Directors - October 20, 2005 Applied NeuroSolutions’ Alzheimer’s Test Expected to be Featured on “Lou Adler’s Medical Journal” Radio Report - October 18, 2005 Applied NeuroSolutions Takes First Step In Commercialization of Diagnostic Alzheimer’s Disease Test - September 08, 2005 Applied NeuroSolutions, Inc. President and CEO Interviewed on “Business Talk This Morning” Radio Show - August 31, 2005 Applied NeuroSolutions Profiled in Chicago Sun-Times - August 08, 2005 Applied NeuroSolutions' Diagnostic Alzheimer's Disease Test Focus of Story on CBS News TV Stations - August 03, 2005 Applied NeuroSolutions Adds Jay B. Langner, Board Chairman of Montefiore Medical Center, to its Board of Directors - July 26, 2005 Applied NeuroSolutions Sees Abnormal Cell Division as Possible Precursor of Alzheimer's Disease- June 20, 2005 Applied NeuroSolutions Announces Research Program For Novel Approach To Alzheimer's Disease Therapeutics- June 06, 2005 Applied NeuroSolutions Biomarker May Predict Alzheimer's Disease Progression - May 25, 2005 Applied NeuroSolutions Ready to Ship First Research Mouse to Exhibit Key Alzheimer's Pathology - April 06, 2005 Applied NeuroSolutions Receives U.S. Patent on Alzheimer's Blood Test Technology - March 10, 2005 Johns Hopkins "Memory Bulletin" Comments on Applied NeuroSolutions Alzheimer's Disease Diagnostic - February 28, 2005 bioMérieux to License Applied NeuroSolutions’ Technology to Diagnose Alzheimer’s Disease - December 13, 2004 Applied NeuroSolutions’ p-tau 231 Assay Greatly Improves Early Stage Alzheimer’s Disease Detection Journal of Internal Medicine Study Shows - September 30, 2004 Applied NeuroSolutions Announces Resignation of Chief Executive Officer and Elevation of John F. DeBernardis, Ph.D. to Chief Executive Officer - September 28, 2004 Dr. Peter Davies Reviews And Questions Conventional Approaches In Alzheimer’s Disease Research - July 21, 2004 Applied Neurosolutions' (Otc Bb: Apns) Biomarker Improves On Early Diagnosis Of Alzheimer’s Disease - July 20, 2004 Applied Neurosolutions’ Bio-Marker Determined To Be Useful In Diagnosing Mildly Cognitively Impaired (Mci) Patients – Assay May Detect Early-Stage Alzheimer’s Disease In Patients - July 19, 2004 Applied Neurosolutions’ Founding Scientist Co-Chairs Alzheimer’s Panel To Examine New Research Models - July 19, 2004 Applied NeuroSolutions Appoints New Board Member - June 18, 2004 APNS Announces Delisting of Unauthorized Listing on Berlin-Bremen Stock Exchange - June 2, 2004 Applied NeuroSolutions Completes $8 Million Private Placement Converts Bridge Loans to Equity - Feb. 12, 2004 Independent Study Concludes Applied NeuroSolutions’ Alzheimer’s Test Exceeds Industry Goals and Standards - Jan. 26, 2004 Applied NeuroSolutions’ Founding Scientist Receives Ten Year NIH Award - Dec. 15, 2003 APNS Discusses Diagnosing Alzheimer's Disease on CEOcast Today - Dec. 10, 2003 Hemoxymed IS NOW Applied NeuroSolutions, Inc. - Nov. 25, 2003 Applied NeuroSolutions Signs Agreement with Novartis - Nov. 19, 2003 Hemoxymed, Inc. To Be Re-Named Applied NeuroSolutions, Inc. - Oct. 14, 2003 Hemoxymed to Market Unique Animal Model for Alzheimer's Disease - Sept. 16, 2003